12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Nimbus Discovery preclinical data

Nimbus said ND-630 inhibited hepatic fatty acid synthesis with an ED50 of 0.14 mg/kg and stimulated whole body fatty acid oxidation at a minimum effective dose of...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >